For Immediate Release: October 27, 2017
513-579-9911 x 12523
Medpace Hosts Complimentary Webinar:
Rare Disease Disorders and CNS Drug Development – Paving the Way for Precision Medicine
CINCINNATI, OH – (October 27, 2017) – Join medical and operational experts from Medpace as they explore the shifting clinical development landscape of CNS drug development. Topics for discussion will include:
- The shifting clinical development landscape – Discussion of new genetic findings in Parkinson’s Disease, Dementia, and ALS, as well as the heritability of psychiatric disorders
- The history of treatment of rare diseases with CNS manifestations – successes and failures
- Operational lessons-learned in identifying, enrolling and retaining rare disease populations in clinical trials
- New approaches to deliver disease specific targeted therapies to the CNS
WEBINAR: Rare Disease Disorders and CNS Drug Development – Paving the Way for Precision Medicine
DATE: Wednesday, November 15, 2017
TIME: 11am EST / 4pm GMT (UK) / 5pm CET (EU-Central)
DURATION: 60 minutes
About the Presenters
James Vornov, MD, PhD, Vice President of Medical Affairs, Neurology, Medpace
Dr. Vornov is an internationally known clinician-scientist with broad experience in both neuroscience and CNS drug development. He has worked in multiple CNS therapeutic areas having directed programs in depression, suicidal ideation, Parkinson’s disease, stroke, neuropathic pain, diabetic and chemotherapy-induced peripheral neuropathy, anesthesia and brain tumors. He has particular expertise in the rapid transition of compounds from the laboratory to clinical proof of concept through the use of technologies such as biomarkers, PK/PD modeling, adaptive design and clinical trial simulation. Dr. Vornov received his B.A. in Biology from Columbia University and his M.D. and Ph.D. from Emory University School of Medicine. He trained in Neurology at the Johns Hopkins Medical School where he served on the faculty for 10 years prior to transitioning to industry.
Richard Scheyer, MD, Vice President of Medical Affairs, Neurology, Pharmacology, Medpace
Dr. Richard Scheyer is a board certified neurologist with over 30 years of professional medical experience which includes 20 years dedicated to clinical drug development. He is a pioneer in translational medicine and Phase I/II drug development, with special interest in early demonstration of clinical efficacy. Dr. Scheyer received his B.S. in Physics from Stanford University, his M.D. from The State University of New York, Upstate Medical University, and completed residency training in Neurology and fellowship training in Epilepsy and Clinical Pharmacology at Yale University before joining the Yale faculty, serving as Associate Professor of Neurology. Prior to joining Medpace, Dr. Scheyer held a number of leadership roles at biopharmaceutical firms where he was responsible for clinical, biomarker, and pharmacogenomic strategy and execution for more than 70 development candidates across therapeutic areas. Experience includes small molecule, macromolecular, and genetic therapies for common and rare neurologic disease.
Terence Eagleton, MBBS, BSc, Senior Medical Director, Rare Diseases, Medpace
Dr. Terence Eagleton is an accomplished pharmaceutical physician who has worked in the biopharma industry for over 17 years. He has worked in all phases of international clinical research and global medical affairs in a wide variety of therapeutic areas but with a particular focus on rare metabolic and endocrine disorders. During his career, he has contributed significantly to the clinical development and commercialization of numerous innovative therapies for rare and ultra-rare indications that include, but are not limited to, Morquio Syndrome Type A, Hunter Syndrome, Hurler Syndrome, Gaucher Disease, Anderson-Fabry Disease, Lysosomal Acid Lipase Deficiency, Pompe Disease, Hereditary Angioedema, and X-linked Hypophosphatemia. Dr. Eagleton received his Bachelor of Science Degree (Honours) in Physiology and Medical Degree at University College London and following qualification, trained as a surgeon with a particular interest in Trauma Management and Patient Critical Care.
Michelle Petersen, MS, Sr. Associate Director, Clinical Trial Management, Medpace
Michelle Petersen has 10 years’ experience in preclinical and clinical research which includes managing global studies in Phases I through III of development. She has managed multiple global rare/ultra-rare disease trials with a focus on neuromuscular and pediatric disorders. Ms. Petersen is a member of Medpace’s specialized Rare Disease Consortium and Patient Recruitment Team, and she is adept in developing strategies necessary to address the potential challenges of recruitment and logistical requirements for studies of this nature. Ms. Petersen holds a Master of Science degree in Physiology from the University of Cincinnati College of Medicine.
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its physician-led, high-science, and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 2,500 people across 35 countries.